Pharmacogenetic testing company genedrive plc (AIM: GDR) announced on Wednesday that the National Institute for Health and Care Excellence (NICE) has officially recommended the Genedrive CYP2C19-ID Kit in its final guidance. This decision designates the Genedrive test as the preferred point-of-care platform for genotype testing prior to clopidogrel treatment for stroke patients within the NHS.

With UKCA certification and completion of the DEVOTE clinical phase, Genedrive is set to commercialize the CYP2C19-ID Kit in the UK and Middle Eastern markets. The kit uses a non-invasive cheek swab to identify key genetic variants of the CYP2C19 gene, aiding clinicians in promptly optimising treatment plans.

NICE's assessment highlighted the kit's comprehensive genetic coverage, cost-effectiveness and ease of integration with patient electronic healthcare systems. This recommendation underscores Genedrive's competitive edge in the pharmacogenetic testing market.

Headquartered in the UK, genedrive's portfolio includes the Genedrive MT-RNR1 ID Kit and the Genedrive CYP2C19 ID Kit, both validated in collaboration with NHS partners. These tests provide rapid, reliable genetic information to enhance treatment decisions, particularly in emergency healthcare settings.

Global stroke statistics from the World Stroke Organization and the Stroke Association emphasise the importance of effective stroke management. Clopidogrel, an antiplatelet drug metabolized by the CYP2C19 gene, is crucial for stroke treatment, but genetic variations can affect its efficacy in up to 60% of patients in certain ethnic groups.

The company aims to accelerate growth through increased market sales, geographic expansion and strategic M&A, operating from its Manchester facilities.